On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
view original post